OBJECTIVES: To evaluate the effectiveness of Glucagon-like peptide-1 receptor agonist (GLP-1 RA) liraglutide on glycemic control and cardiovascular outcomes among Chinese patients with Type 2 Diabetes Mellitus (T2DM).
METHODS: Data were collected from the hospital information system database covering 10 tertiary hospitals in Tianjin, China.
